X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2629) 2629
Publication (332) 332
Book Review (29) 29
Newsletter (12) 12
Book Chapter (6) 6
Magazine Article (6) 6
Newspaper Article (4) 4
Conference Proceeding (3) 3
Trade Publication Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2258) 2258
hiv infections - drug therapy (1603) 1603
male (1460) 1460
female (1299) 1299
adult (1270) 1270
index medicus (1205) 1205
ritonavir (1121) 1121
infectious diseases (1028) 1028
ritonavir - adverse effects (1015) 1015
middle aged (959) 959
hiv protease inhibitors - adverse effects (863) 863
ritonavir - therapeutic use (812) 812
hiv (786) 786
pharmacology & pharmacy (749) 749
drug therapy, combination (721) 721
ritonavir - administration & dosage (689) 689
anti-hiv agents - adverse effects (648) 648
hiv protease inhibitors - therapeutic use (623) 623
protease inhibitors (606) 606
anti-hiv agents - therapeutic use (566) 566
immunology (554) 554
antiretroviral therapy (548) 548
lopinavir (529) 529
treatment outcome (492) 492
drug interactions (474) 474
hiv protease inhibitors - administration & dosage (452) 452
drug therapy (427) 427
anti-hiv agents - administration & dosage (399) 399
viral load (387) 387
hiv infection (386) 386
hiv infections - virology (380) 380
pharmacokinetics (378) 378
antiviral agents (359) 359
virology (359) 359
cd4 lymphocyte count (340) 340
therapy (328) 328
microbiology (326) 326
hiv-1 - drug effects (320) 320
hiv infections - complications (307) 307
human immunodeficiency virus--hiv (302) 302
safety (288) 288
aged (279) 279
efficacy (274) 274
risk factors (265) 265
lopinavir/ritonavir (262) 262
antiretroviral drugs (259) 259
aids (256) 256
hiv-1 (256) 256
ritonavir - pharmacokinetics (254) 254
highly active antiretroviral therapy (251) 251
adolescent (247) 247
dosage and administration (245) 245
drug combinations (242) 242
tenofovir (242) 242
hiv protease inhibitors - pharmacokinetics (239) 239
drug administration schedule (235) 235
research (234) 234
antiretroviral therapy, highly active - adverse effects (229) 229
atazanavir sulfate (227) 227
darunavir (227) 227
health aspects (225) 225
pyrimidinones - adverse effects (225) 225
aids/hiv (214) 214
antiretroviral therapy, highly active (213) 213
hiv-infected patients (209) 209
sulfonamides - adverse effects (206) 206
pyridines - adverse effects (202) 202
young adult (202) 202
protease inhibitor (201) 201
rna, viral - blood (198) 198
efavirenz (192) 192
infection (190) 190
atazanavir (188) 188
care and treatment (187) 187
human-immunodeficiency-virus (187) 187
pyrimidinones - therapeutic use (183) 183
prospective studies (182) 182
reverse transcriptase inhibitors - therapeutic use (178) 178
sulfonamides - therapeutic use (175) 175
active antiretroviral therapy (174) 174
human immunodeficiency virus (172) 172
anti-hiv agents - pharmacokinetics (170) 170
hiv infections - blood (170) 170
virus diseases (167) 167
ritonavir - pharmacology (165) 165
combination (163) 163
hiv infections - immunology (163) 163
pyridines - therapeutic use (163) 163
complications and side effects (162) 162
retrospective studies (161) 161
sulfonamides - administration & dosage (161) 161
hiv-1-infected patients (160) 160
clinical trials (155) 155
oligopeptides - adverse effects (154) 154
pyrimidinones - administration & dosage (154) 154
reverse transcriptase inhibitors - adverse effects (152) 152
patients (148) 148
analysis (147) 147
indinavir (147) 147
lamivudine (145) 145
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2528) 2528
Spanish (60) 60
German (30) 30
French (24) 24
Japanese (3) 3
Russian (3) 3
Danish (2) 2
Dutch (2) 2
Italian (2) 2
Korean (2) 2
Chinese (1) 1
Czech (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 05/2018, Volume 47, Issue 9, pp. 1296 - 1305
Summary Background Interferon‐free regimens are associated with high sustained virological response; however, associated adverse effects have yet to be fully... 
Complications and side effects | Care and treatment | Anemia | Analysis | Liver | Mortality | Interferon | Rankings | Bilirubin | Biological response modifiers | Hepatitis C | Liver cirrhosis | Ritonavir | Hepatocellular carcinoma | Patients | Ribavirin | Incidence | Hepatitis | Cirrhosis | Side effects | Hyperbilirubinemia | Hemoglobin | Hepatitis C virus | Platelets
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 6/2011, Volume 203, Issue 12, pp. 1791 - 1801
Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus... 
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | INFECTIOUS DISEASES | EFFICACY | INITIATION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | COMBINATION | OSTEOPOROSIS | HIV-INFECTED PATIENTS | WOMEN | THERAPY | COHORT | HEALTH | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Major and Brief Reports
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
OBJECTIVENew potent direct-acting antiviral (DAA) regimens against hepatitis C virus have been approved in recent years. However, information about the rate of... 
ribavirin | ledipasvir and sofosbuvir | hepatitis C virus | ombitasvir and dasabuvir | genotype 1 | adverse events | randomized | direct-acting antivirals | paritaprevir | ACUTE LIVER-FAILURE | VIRUS-INFECTION | SOFOSBUVIR | HCV INFECTION | REAL-WORLD EFFECTIVENESS | SUSTAINED VIROLOGICAL RESPONSE | DASABUVIR | GENOTYPE 1B CIRRHOSIS | RITONAVIR-BOOSTED PARITAPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Fatigue - chemically induced | Drug Therapy, Combination - adverse effects | Ritonavir - adverse effects | Adult | Female | Fluorenes - adverse effects | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Headache - chemically induced | Antiviral Agents - therapeutic use | Anemia - chemically induced | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Uracil - adverse effects | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Viral Load - drug effects | Uracil - analogs & derivatives | Drugs | Antiviral agents | Complications and side effects | Treatment outcome | Usage | Analysis | Adverse and side effects | Hepatitis C | Drug therapy | Risk factors
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Journal Article